Lipocine Inc. (NASDAQ:LPCN) Sees Significant Drop in Short Interest

Lipocine Inc. (NASDAQ:LPCN) was the target of a significant drop in short interest in December. As of December 31st, there was short interest totalling 48,500 shares, a drop of 21.0% from the December 15th total of 61,400 shares. Based on an average trading volume of 29,800 shares, the days-to-cover ratio is presently 1.6 days. Approximately 0.9% of the shares of the stock are short sold.

Institutional Investors Weigh In On Lipocine

An institutional investor recently bought a new position in Lipocine stock. Dimensional Fund Advisors LP purchased a new stake in Lipocine Inc. (NASDAQ:LPCN) in the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor purchased 11,870 shares of the specialty pharmaceutical company’s stock, valued at approximately $98,000. Dimensional Fund Advisors LP owned 0.22% of Lipocine at the end of the most recent reporting period. Hedge funds and other institutional investors own 9.11% of the company’s stock.

Lipocine Stock Performance

Shares of LPCN stock traded down $0.08 during trading hours on Friday, reaching $4.37. The company had a trading volume of 42,027 shares, compared to its average volume of 29,612. Lipocine has a 12-month low of $3.20 and a 12-month high of $11.79. The company has a market capitalization of $23.38 million, a price-to-earnings ratio of -5.75 and a beta of 1.23. The stock has a fifty day moving average of $4.89 and a 200-day moving average of $5.04.

Lipocine (NASDAQ:LPCN) last issued its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.44) earnings per share (EPS) for the quarter. On average, analysts forecast that Lipocine will post -0.78 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. StockNews.com started coverage on Lipocine in a report on Friday. They issued a “hold” rating on the stock. Alliance Global Partners began coverage on shares of Lipocine in a research note on Tuesday, September 24th. They issued a “buy” rating and a $10.00 price target on the stock.

About Lipocine

Lipocine Inc, a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate.